Trial Profile
A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Vandetanib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms FURVA
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 11 Dec 2019 Status changed from completed to active, no longer recruiting.
- 22 Jan 2016 Status changed from recruiting to active, no longer recruiting.